Cargando…

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?

Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently incorporated into international guidelines for several different indications in prostate cancer (PCa) patients. However, there are still some open questions regarding the role of PSMA ligand PET in castration-resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urso, Luca, Filippi, Luca, Castello, Angelo, Marzola, Maria Cristina, Bartolomei, Mirco, Cittanti, Corrado, Florimonte, Luigia, Castellani, Massimo, Zucali, Paolo, Bruni, Alessio, Sabbatini, Roberto, Dominici, Massimo, Panareo, Stefano, Evangelista, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672135/ https://www.ncbi.nlm.nih.gov/pubmed/38002742 http://dx.doi.org/10.3390/jcm12227130

Ejemplares similares

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives
por: Urso, Luca, et al.
Publicado: (2022)

The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review
por: Urso, Luca, et al.
Publicado: (2023)

PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review
por: Urso, Luca, et al.
Publicado: (2022)

Lutathera(®) Orphans: State of the Art and Future Application of Radioligand Therapy with (177)Lu-DOTATATE
por: Urso, Luca, et al.
Publicado: (2023)

The Role of [(68)Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review
por: Caracciolo, Matteo, et al.
Publicado: (2022)

Comparison of MRI vs. [(18)F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives
por: Caracciolo, Matteo, et al.
Publicado: (2023)

Relevance of Volumetric Parameters Applied to [(68)Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
por: Urso, Luca, et al.
Publicado: (2023)

The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria
por: Castello, Angelo, et al.
Publicado: (2022)

Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report
por: Panareo, Stefano, et al.
Publicado: (2020)

Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review
por: Urso, Luca, et al.
Publicado: (2022)

Clinical-Diagnostic Relevance of Breast “Incidentaloma” Detected During 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography: Correlation with Radiological Imaging and Histopathology
por: Panareo, Stefano, et al.
Publicado: (2021)

Glucose Metabolism Modification Induced by Radioligand Therapy with [(177)Lu]Lu/[(90)Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
por: Urso, Luca, et al.
Publicado: (2022)

The Value of Semiquantitative Parameters Derived from (18)F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer
por: Urso, Luca, et al.
Publicado: (2022)

(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans
por: Uccelli, Licia, et al.
Publicado: (2021)

Incidental Findings of Acute Myeloid Leukemia in Sjögren's Syndrome Detected by Nuclear Medicine Techniques
por: Castello, Angelo, et al.
Publicado: (2022)

Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report
por: Nieri, Alberto, et al.
Publicado: (2023)

18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?
por: Urso, Luca, et al.
Publicado: (2022)

Role of 18F-FDG PET/CT in evaluating lymph node status in patients with head and neck squamous cell carcinoma
por: Bianchini, Chiara, et al.
Publicado: (2023)

The Role of [(18)F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach
por: Urso, Luca, et al.
Publicado: (2022)

Rhenium Radioisotopes for Medicine, a Focus on Production and Applications
por: Uccelli, Licia, et al.
Publicado: (2022)

PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature
por: Evangelista, Laura, et al.
Publicado: (2023)

(18)F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy
por: Quartuccio, Natale, et al.
Publicado: (2023)

[(18)F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review
por: Filippi, Luca, et al.
Publicado: (2023)

Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008–2018)
por: Uccelli, Licia, et al.
Publicado: (2019)

Correction: Uccelli, L., et al. Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008–2018). Molecules 2019, 24, 640
por: Uccelli, Licia, et al.
Publicado: (2019)

Missing sentinel lymph node in cutaneous melanoma
por: Dellavedova, Luca, et al.
Publicado: (2015)

Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000–2022)
por: Riondato, Mattia, et al.
Publicado: (2023)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma
por: Harris, Nathanial, et al.
Publicado: (2023)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Influence of Storage Temperature on Radiochemical Purity of (99m)Tc-Radiopharmaceuticals
por: Uccelli, Licia, et al.
Publicado: (2018)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer
por: Shi, Sheng-Jia, et al.
Publicado: (2019)

Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield
por: Iudicello, Antonella, et al.
Publicado: (2022)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2j2rihsemi0e2rq3q67euoo4a9